CING Cingulate Inc. Insider Trading

Director Thomas Jeffrey Hargroves purchases 97,276 shares of CING via private placement at $5.04; retains 92,821 derivative shares via warrants and options.

Director Thomas Jeffrey Hargroves acquired 97,276 shares at $5.04 on 2026-02-13 as part of a private placement, not a discretionary open-market purchase. His post-transaction holdings of 97,468 non-derivative shares represent a +50664.6% increase from his pre-transaction position of 192 shares, but this figure reflects only the registered component; he maintains 92,821 additional shares through derivative holdings (77,821 warrants and 15,000 options). The company is unprofitable, with net income of $-9,312,089.00 over its most recent full fiscal year, and the stock has declined -42.4% over the past 90 days and -61.9% from its 52-week high of $11.89. The private-placement structure means this purchase does not constitute a discretionary buying signal, and the substantial derivative position alongside modest non-derivative additions suggests his overall conviction is expressed through derivative vehicles rather than direct share accumulation.

CFO Callahan bought 4,864 shares of CING at $5.04 (2026-02-06), raising holdings 2494.4%; cluster buy pattern detected; 3 prior buys all well-timed at 90d mark

Jennifer L. Callahan, SVP and CFO, purchased 4,864 shares at $5.04, increasing her position from 195 shares to 5,059 shares—a 2494.4% increase in her stake. Her cross-ticker track record shows 3 prior open-market buys with an average 90-day return of +10045.2% and a 100% win rate, and at Cingulate specifically, all 3 prior buys were well-timed: her 2023-09-15 purchase returned +5078.4% over 90 days, her 2023-05-15 buy returned +12969.3% over 90 days, and her 2023-05-12 purchase returned +12087.8% over 90 days. The current transaction occurs within a cluster pattern, with 3 other insiders also buying within the past 14 days. However, the company is unprofitable, reporting a net loss of $-7,341,062.00 over its most recent full fiscal year.

EVP/CMO Brams Matthew buys 1,946 shares at $5.04; 3 other insiders also bought within 14 days—cluster pattern amid unprofitable fundamentals.

Brams Matthew, EVP and Chief Medical Officer of Cingulate Inc., purchased 1,946 shares at $5.04 on 2026-02-06, increasing his post-transaction holdings to 4,656 shares (+71.8% vs pre-transaction holdings of 2,710 shares). This transaction occurred within a broader pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated or reinforcing insider confidence. However, the company's fundamentals present a critical counterpoint—net income was $-7,341,062.00 over the most recent full fiscal year, and market cap stands at $46,083,217.40, indicating a pre-revenue or unprofitable-stage entity. The transaction price of $5.04 sits 26.1% below the current price of $6.82, and the stock has risen +47.3% over 30 days and +79.5% over 90 days, suggesting recent momentum. Investors should note the apparent disconnect: multiple insiders are buying into a materially unprofitable business experiencing sharp recent appreciation.

CEO Schaffer buys 6,809 shares of CING at $5.04; holdings +202.3%, cluster buy pattern amid -$7.3M net income

Chief Executive Officer Schaffer Shane J. purchased 6,809 shares at $5.04 per share on 2026-02-06, increasing his holdings by 202.3% from 3,366 to 10,175 shares. This buy occurs within a cluster pattern where 3 other insiders also purchased within the past 14 days, suggesting coordinated or concurrent confidence. The transaction is notable given the company's negative net income of $-7,341,062.00 over its most recent full fiscal year; despite unprofitability, the CEO is materially expanding his ownership stake. The stock has appreciated 47.3% over 30 days and 79.5% over 90 days from prior levels, and currently trades at $6.82—35.2% above the purchase price—leaving room to assess whether this accumulation aligns with operational recovery or positions ahead of strategic shifts.

Director Werth buys 19,455 shares of CING at $5.04; stake rises to 117,449 shares amid unprofitable fundamentals and 47.3% 30-day rally.

Director Peter J. Werth purchased 19,455 shares at $5.04 on 2026-02-06, increasing his position to 117,449 shares (+19.9% vs pre-transaction holdings). The stock has rallied 47.3% over the past 30 days and 79.5% over 90 days, yet remains 11.4% below its 52-week high of $7.70. The buy occurs within a cluster pattern: 3 other insiders also purchased within the past 14 days. However, the company is currently unprofitable with a full-year net income of $-7,341,062.00, limiting the financial foundation underlying the recent price momentum. Werth's cross-ticker track record shows strong past execution (1 prior buy at this same ticker with 90d return of +16089.6%), though that historical pattern reflects conditions in prior periods and does not necessarily predict this transaction's outcome in an unprofitable environment.